Taewoo Lee, MD
Nephrology · Winston Salem, NCNPI 1033649819
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Travere Therapeutics, Inc. at 39.8% of the total. Among nephrology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $399.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$6K
- EDAP Technomed Inc$4K
- Calliditas Therapeutics US Inc.$2K
- Amgen$2K
- Aurinia Pharma U.S., Inc.$316
- Veloxis Pharmaceuticals, Inc.$125
- plus $348 from 3 others
Across 3 payments — averaging $4364.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurinia Pharma U.S., Inc.$13K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$94
What the payments were for
- Consulting fees$7,35053%
- Travel & lodging$5,09136%
- Food & beverage$1,55711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 14 | $5,578 |
| EDAP Technomed Inc | 8 | $3,646 |
| Calliditas Therapeutics US Inc. | 2 | $2,255 |
| Amgen | 3 | $1,730 |
| Aurinia Pharma U.S., Inc. | 4 | $316 |
| Veloxis Pharmaceuticals, Inc. | 1 | $125 |
| GSK | 1 | $122 |
| Bayer | 1 | $122 |
| OPKO Pharmaceuticals, LLC | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,999 in reported general payments places this provider in the 90th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $43,976 |
| FarxigaDapagliflozin Propanediol | 28 | $31,454 |
| Chlorthalidone | 15 | $202 |
| Carvedilol | 30 | $152 |
| Allopurinol | 28 | $133 |
| Amlodipine Besylate | 31 | $128 |
| Losartan Potassium | 15 | $94 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Winston Salem
- Barry FreedmanWinston Salem$67K
- Michael RoccoWinston Salem$21K
- Anthony BleyerWinston Salem$20K
- Nicholas McLeanWinston Salem$14K
- Andrew SpanglerWinston Salem$9K
- Christopher MarshallWinston Salem$9K
- Scott SatkoWinston Salem$9K
- Alexander HadleyWinston Salem$9K
- Jim EllisonWinston Salem$8K
- Gregory GreenwoodWinston-Salem$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.